Valuation : Shanghai Rendu Biotechnology Co., Ltd.

Market Cap 1.86B 276M 238M 223M 204M 381M 26.1B 384M 2.64B 1.03B 13.34B 1.04B 1.01B 42.95B P/E 2024
-179x
P/E 2025 186x
Enterprise Value 1.04B 155M 133M 125M 114M 214M 14.64B 215M 1.48B 576M 7.48B 582M 569M 24.1B EV / Sales 2024
3.31x
EV / Sales 2025 6.55x
Free-Float
48.41%
Yield 2024
0.56%
Yield 2025 2.38%
08-28 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
05-14 Shanghai Rendu Biotechnology's share trade to resume from May 15 RE
05-13 Nanjing Haijing Pharmaceutical Co., Ltd. agreed to acquire 21.25% stake in Shanghai Rendu Biotechnology Co., Ltd. from Ju Jinliang, Qiming Weichuang Venture Capital Management Company Limited, Runcong Enterprise Management Center (Limited Partnership), China International Capital Corporation Limited, Qiming Ventures Fund III, Changzhou Jinxin Venture Capital Co., Ltd. and Novel Praise Limited for approximately CNY 520 million. CI
05-08 Rendu Biotech's Controlling Shareholder Eyes Share Transfer Deal MT
05-07 Trading in Shanghai Rendu Biotechnology's shares to halt RE
04-28 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
30/10/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/08/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
29/04/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
29/10/24 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
29/08/24 Shanghai Rendu Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 CI
1 day-0.75%
1 week-0.29%
Current month-3.76%
1 month-0.31%
3 months-2.72%
6 months-5.86%
Current year-1.10%
1 week 47.48
Extreme 47.48
50.51
1 month 46.03
Extreme 46.03
50.51
Current year 40
Extreme 40
63.56
1 year 40
Extreme 40
63.56
3 years 22.5
Extreme 22.5
63.56
5 years 22.5
Extreme 22.5
72
10 years 22.5
Extreme 22.5
72
Manager TitleAgeSince
Chief Executive Officer 43 08/12/2022
Chief Tech/Sci/R&D Officer 60 12/06/2007
Director of Finance/CFO 52 31/07/2015
Director TitleAgeSince
Chairman 60 12/06/2007
Director/Board Member 43 30/04/2008
Director/Board Member 61 20/10/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%-0.29%-6.71%+3.91% 278M
-2.31%-2.25%+157.28%+347.10% 21.61B
-2.24%-0.80%-35.48%-21.96% 10.39B
-1.61%+1.70%+361.21%+19.26% 8.24B
-2.27%-3.32%-31.83% - 7.16B
-0.00%+0.19%+87.59%+52.85% 6.59B
+2.34%+1.42%-20.55%-18.65% 5.88B
-1.59%-1.41%-8.50%-21.61% 4.42B
-0.62%-2.61%+75.81%+82.60% 4.25B
+1.82%-1.61%-19.23%-27.90% 2.75B
Average -0.63%-1.45%+55.96%+46.18% 7.16B
Weighted average by Cap. -1.19%-1.90%+90.33%+121.88%

Financials

2024 2025
Net sales 177M 26.39M 22.71M 21.31M 19.5M 36.39M 2.49B 36.68M 252M 98.17M 1.28B 99.11M 96.95M 4.11B 162M 24.1M 20.74M 19.46M 17.8M 33.23M 2.28B 33.49M 230M 89.64M 1.16B 90.5M 88.53M 3.75B
Net income -7.81M -1.16M -1M -939K -859K -1.6M -110M -1.62M -11.1M -4.32M -56.16M -4.37M -4.27M -181M 10.09M 1.5M 1.29M 1.21M 1.11M 2.07M 142M 2.09M 14.34M 5.58M 72.52M 5.64M 5.51M 234M
Net Debt -798M -119M -102M -95.83M -87.67M -164M -11.22B -165M -1.13B -441M -5.73B -446M -436M -18.47B -815M -121M -104M -97.87M -89.54M -167M -11.46B -168M -1.16B -451M -5.86B -455M -445M -18.86B
Logo Shanghai Rendu Biotechnology Co., Ltd.
Shanghai Rendu Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production, and sales of molecular diagnostic reagents and equipment. The Company mainly operates three businesses. The reagent business is mainly engaged in the research, development, production, and sales of molecular diagnostic reagents for reproductive tract infections, respiratory tract infections, enteroviruses, and bloodborne infectious diseases, as well as other reagent products such as sample preservation solutions and nucleic acid extraction reagents. The instrument business is mainly engaged in the research, development, production, and sales of molecular diagnostic instruments such as the fully automated nucleic acid detection and analysis system (AutoSAT). The testing business is mainly engaged in the provision of clinical testing services, including pathogen detection for the genitourinary system, bloodborne pathogens, respiratory system, and digestive system.
Employees
239
Date Price Change Volume
03/09/26 CN¥47.84 -0.75% 482,098
03/09/26 CN¥48.20 -1.51% 457,074
02/09/26 CN¥48.94 -2.18% 474,959
01/09/26 CN¥50.03 +0.64% 448,710
31/08/26 CN¥49.71 +3.76% 705,330
  1. Stock Market
  2. Stocks
  3. 688193 Stock